Literature DB >> 3086416

Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.

W Flameng, J Vanhaecke, D C Stump, F Van de Werf, W Holmes, W A Guenzler, L Flohe, D Collen.   

Abstract

An occlusive thrombus was produced by thrombin-induced coagulation in the left anterior descending coronary artery of 18 open chest baboons. In six control animals, occlusive thrombosis persisting for 4 hours resulted in a large transmural infarct (66 +/- 4% of the perfusion area, mean +/- SEM). In six animals, single chain urokinase-type plasminogen activator, obtained by recombinant deoxyribonucleic acid (DNA) technology, was infused intravenously at a rate of 20 micrograms/kg per min for 60 minutes after approximately 45 minutes of coronary thrombosis. Persistent reperfusion occurred within 21 +/- 4 minutes (mean +/- SD). The mean duration of occlusion before reperfusion was 72 +/- 6 minutes. Recanalization resulted in a reduction of infarct size (42 +/- 4%, p less than 0.01 versus control animals). Myocardial blood flow in the perfusion area of the left anterior descending coronary artery was 107% of normal 2.5 hours after recanalization. The infusion of recombinant single chain urokinase-type plasminogen activator was not associated with systemic activation of the fibrinolytic system, fibrinogen breakdown or evident bleeding. In six baboons recombinant low molecular weight urokinase (molecular weight 33,000) was infused intravenously at a rate of 20 micrograms/kg per min for 60 minutes after approximately 45 minutes of coronary thrombosis. Persistent reperfusion occurred within 14 +/- 5 minutes (p less than 0.05 versus recombinant single chain urokinase-type plasminogen activator). The mean duration of occlusion was 69 +/- 14 minutes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086416     DOI: 10.1016/s0735-1097(86)80101-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

1.  Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration.

Authors:  H R Michels; J J Hoffman; F W Bär
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

2.  Saruplase in Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

4.  A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.